Allspring Global Investments Holdings LLC Acquires 1,058 Shares of Catalent, Inc. (NYSE:CTLT)

Allspring Global Investments Holdings LLC raised its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 12.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,745 shares of the company’s stock after acquiring an additional 1,058 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Catalent were worth $590,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Gamco Investors INC. ET AL boosted its stake in shares of Catalent by 403.3% during the first quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company’s stock valued at $1,428,000 after purchasing an additional 20,273 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Catalent by 2,792.9% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock valued at $29,150,000 after purchasing an additional 498,540 shares during the period. UniSuper Management Pty Ltd boosted its stake in shares of Catalent by 509.4% during the first quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company’s stock valued at $1,028,000 after purchasing an additional 15,217 shares during the period. Swedbank AB purchased a new stake in shares of Catalent during the first quarter valued at approximately $1,659,000. Finally, SG Americas Securities LLC boosted its stake in shares of Catalent by 147.4% during the first quarter. SG Americas Securities LLC now owns 99,588 shares of the company’s stock valued at $5,622,000 after purchasing an additional 59,339 shares during the period.

Insider Activity at Catalent

In related news, insider David Mcerlane sold 1,994 shares of the stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.31% of the stock is currently owned by insiders.

Analysts Set New Price Targets

CTLT has been the subject of a number of analyst reports. Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a research note on Thursday, July 11th. StockNews.com started coverage on Catalent in a research note on Saturday, October 12th. They issued a “hold” rating for the company. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. Nine analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $59.83.

Catalent Stock Up 0.2 %

Shares of Catalent stock opened at $58.73 on Friday. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96. The company has a 50-day moving average of $60.07 and a 200 day moving average of $57.93. The firm has a market cap of $10.66 billion, a price-to-earnings ratio of -10.69, a PEG ratio of 2.07 and a beta of 1.15. Catalent, Inc. has a 1 year low of $32.38 and a 1 year high of $61.20.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The company had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.23 billion. As a group, sell-side analysts anticipate that Catalent, Inc. will post 0.95 earnings per share for the current fiscal year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.